Jetrea Side Effects

Generic Name: ocriplasmin ophthalmic

Note: This page contains information about the side effects of ocriplasmin ophthalmic. Some of the dosage forms included on this document may not apply to the brand name Jetrea.

Not all side effects for Jetrea may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.

For the Consumer

Applies to ocriplasmin ophthalmic: intraocular solution

In addition to its needed effects, some unwanted effects may be caused by ocriplasmin ophthalmic (the active ingredient contained in Jetrea). In the event that any of these side effects do occur, they may require medical attention.

If any of the following side effects occur while taking ocriplasmin ophthalmic, check with your doctor or nurse immediately:

More common
  • Bloody eyes
  • blurred vision or other change in vision
  • decreased vision
  • eye pain
  • redness of the eye
  • seeing flashes or sparks of light
  • sensitivity of the eye to light
  • tearing
Less common
  • Change in color vision
  • difficulty seeing at night
  • eye discomfort
  • loss of vision
  • seeing floating spots before the eyes, or a veil or curtain appearing across part of vision
  • throbbing pain

Some of the side effects that can occur with ocriplasmin ophthalmic may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:

Less common
  • Dry eyes

For Healthcare Professionals

Applies to ocriplasmin ophthalmic: intraocular solution


The most frequently reported side effects (incidence of 5% to 20% in descending order of frequency) were: vitreous floaters, conjunctival hemorrhage, eye pain, photopsia, blurred vision, macular hole, reduced visual acuity, visual impairment, and retinal edema.


Frequency not reported: Potential for immunogenicity


Common (1% to 10%): Macular edema, anterior chamber cell, photophobia, vitreous detachment, ocular discomfort, iritis, cataract, dry eye, metamorphopsia, conjunctival hyperemia, retinal degeneration, intraocular inflammation, decrease of less than or equal to 3 line of best corrected visual acuity (BCVA), increased intraocular pressure, intraocular hemorrhage, dyschromatopsia
Uncommon (0.1% to 1%): Retinal tear, lens detachment
Frequency not reported: Lens subluxation

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.